healthcare · stock-sale · committee-conflict
Rep. Greg Stanton Sells Up to $250K of Cannabis Giant Trulieve
The House Judiciary Committee member liquidated shares originally acquired through his spouse's executive compensation package.
2026-07-01 — Greg Stanton · TCNNF
Key facts
- Rep. Greg Stanton (D-Ariz.) sold between $100,001 and $250,000 of Trulieve Cannabis Corp. (TCNNF) stock on May 28, 2026.
- The sold shares were originally acquired as part of an executive compensation package for Stanton's spouse during her tenure at Trulieve.
- Stanton serves on the House Judiciary Committee, which oversees federal cannabis decriminalization and scheduling legislation.
- The trade occurred three weeks after Trulieve publicly announced an upcoming DEA scheduling hearing scheduled for June 29, 2026.
Rep. Greg Stanton (D-Ariz.) has systematically wound down his household's exposure to the cannabis industry just as federal regulators prepare to decide its future. On May 28, 2026, the Arizona lawmaker sold between $100,001 and $250,000 of stock in Trulieve Cannabis Corp. (TCNNF), a major multi-state operator.
According to disclosure filings, the transaction was a sale of existing stock, not a new purchase or a direct compensation grant. The shares being liquidated were originally acquired as part of an executive compensation package for Stanton's spouse, Chelsea Overstreet Stanton, during her prior tenure as an executive at Trulieve. This divestment follows a smaller sale of between $15,001 and $50,000 on May 6, representing a phased exit from the volatile asset.
Stanton's decision to liquidate the position carries notable policy undertones. He sits on the House Judiciary Committee, which has direct jurisdiction over federal cannabis decriminalization and scheduling legislation, such as the Marijuana Opportunity Reinvestment and Expungement (MORE) Act.
Members of Congress are required by the STOCK Act to disclose trades within 45 days, and disclosed amounts are reported in ranges. Stanton filed his disclosure on June 26, 29 days after the trade.
The timing of the May 28 sale is also notable. It occurred three weeks after Trulieve's May 7 earnings release, which publicly detailed that the administration had reclassified medical marijuana to Schedule III under the Controlled Substances Act. That filing also noted that an expedited review process and a Drug Enforcement Administration (DEA) scheduling hearing were set to begin on June 29.
Stanton wasn't the only insider trimming holdings ahead of the summer regulatory timeline. In mid-to-late June, Trulieve CEO Kim A. Rivers executed a series of massive open-market sales totaling over 1.7 million shares [3, 4].
For a lawmaker on the committee shaping the future of cannabis policy, clearing the air of potential conflicts ahead of a historic DEA hearing is one way to avoid getting burned.
Sources
- Trulieve 8-K Q1 2026 Results — SEC EDGAR
- Trulieve Q1 2026 Earnings Release Exhibit 99.1 — SEC EDGAR
- Trulieve CEO Form 4 Filing June 17-22 — SEC EDGAR
- Trulieve CEO Form 4 Filing June 23-25 — SEC EDGAR